We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

44 hedge funds and large institutions have $46.1M invested in Viridian Therapeutics in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

650% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 2

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

42% more funds holding

Funds holding: 31 → 44 (+13)

0.19% more ownership

Funds ownership: 1.38% → 1.57% (+0.19%)

20% less capital invested

Capital invested by funds: $57.4M → $46.1M (-$11.3M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
44
Holders Change
+13
Holders Change %
+41.94%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
15
Increased
14
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$3.58M
2
AG
Artal Group
Luxembourg
+$1.12M
3
BW
Biegel & Waller
Maryland
+$746K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$601K
5
BlackRock
BlackRock
New York
+$374K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$1.58M
2
Citigroup
Citigroup
New York
-$302K
3
Barclays
Barclays
United Kingdom
-$41K
4
Deutsche Bank
Deutsche Bank
Germany
-$35.2K
5
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS)
California
-$31.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$28.6M – – –
BlackRock
2
BlackRock
New York
$5.03M +$374K +2,225 +6%
JP Morgan Chase
3
JP Morgan Chase
New York
$2.82M +$3.58M +21,290 New
Northern Trust
4
Northern Trust
Illinois
$1.34M +$302K +1,797 +23%
State Street
5
State Street
Massachusetts
$1.06M +$111K +658 +9%
UOTTAIMCU
6
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$965K – – –
AG
7
Artal Group
Luxembourg
$915K +$1.12M +6,667 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$772K +$601K +3,572 +174%
BW
9
Biegel & Waller
Maryland
$609K +$746K +4,434 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$398K +$25.6K +152 +6%
TCIM
11
TIAA CREF Investment Management
New York
$332K +$12.8K +76 +3%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$250K -$841 -5 -0.3%
SG Americas Securities
13
SG Americas Securities
New York
$250K +$306K +1,819 New
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$231K +$283K +1,682 New
TA
15
Teachers Advisors
New York
$212K -$19.5K -116 -7%
BWP
16
BSW Wealth Partners
Colorado
$203K +$249K +1,482 New
Charles Schwab
17
Charles Schwab
California
$195K – – –
HighTower Advisors
18
HighTower Advisors
Illinois
$194K +$112K +666 +90%
California State Teachers Retirement System (CalSTRS)
19
California State Teachers Retirement System (CalSTRS)
California
$179K -$31.5K -187 -13%
Morgan Stanley
20
Morgan Stanley
New York
$163K +$69.5K +413 +53%
Russell Investments Group
21
Russell Investments Group
United Kingdom
$147K +$180K +1,072 New
New York State Common Retirement Fund
22
New York State Common Retirement Fund
New York
$124K – – –
PWLP
23
Prio Wealth Limited Partnership
Massachusetts
$117K +$145K +860 New
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$114K +$4.04K +24 +3%
Deutsche Bank
25
Deutsche Bank
Germany
$102K -$35.2K -209 -22%
1
2

VRDN Hedge Fund Activity: Q3 2017 in Review

44 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2017, worth a combined $46.1M — down 20% from $57.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new VRDN positions and 2 closed out — a net gain of 13 holders — while 14 added to existing stakes and 8 trimmed.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $3.58M. The largest seller was Goldman Sachs, exiting entirely with an estimated $1.58M sold.

  • 44 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2017, up from 31 in Q2 2017.
  • Funds reported $46.1M of Viridian Therapeutics stock for Q3 2017, down 20% quarter-over-quarter.
  • 15 funds opened new Viridian Therapeutics positions in Q3 2017 and 2 closed out, a net change of +13 holders.
  • The largest Viridian Therapeutics buyer in Q3 2017 was JP Morgan Chase, an estimated $3.58M added.
  • The largest Viridian Therapeutics seller in Q3 2017 was Goldman Sachs, an estimated $1.58M sold.

Based on aggregated 13F filings for Q3 2017.